Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6096566 | Gastroenterology | 2010 | 14 Pages |
Abstract
TcdA and TcdB trigger IL-1β release by activating an ASC-containing inflammasome, a response that contributes to toxin-induced inflammation and damage in vivo. Pretreating mice with the IL-1 receptor antagonist anakinra afforded the same level of protection that was observed in ASCâ/â mice. These data suggest that targeting inflammasome or IL-1β signaling may represent new therapeutic targets in the treatment of CDAD.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Jeffrey Ng, Simon A. Hirota, Olaf Gross, Yan Li, Annegret Ulke-Lemee, Mireille S. Potentier, L. Patrick Schenck, Akosua Vilaysane, Mark E. Seamone, Hanping Feng, Glen D. Armstrong, Jurg Tschopp, Justin A. MacDonald, Daniel A. Muruve, Paul L. Beck,